Benzinga | Aug 26, 2021 10:19AM EDT

Morgan Stanley Maintains Overweight on Horizon Therapeutics, Raises Price Target to $135

Morgan Stanley analyst Michael Ulz maintains Horizon Therapeutics (NASDAQ:HZNP) with a Overweight and raises the price target from $103 to $135.